Insider Selling: Stevanato Group (NYSE:STVN) CFO Sells 4,209 Shares

Stevanato Group S.p.A. (NYSE:STVN) CFO Lago Marco Dal sold 4,209 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €84,558.81. Following the sale, the chief financial officer owned 81,144 shares of the company’s stock, valued at €1,630,182.96. The trade was a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stevanato Group Stock Up 1.9%

NYSE:STVN traded up €0.38 on Monday, hitting €20.65. 501,629 shares of the company’s stock traded hands, compared to its average volume of 541,629. The company has a market cap of $6.25 billion, a PE ratio of 36.87, a price-to-earnings-growth ratio of 1.70 and a beta of 0.77. Stevanato Group S.p.A. has a 1 year low of €12.89 and a 1 year high of €28.00. The company has a current ratio of 1.61, a quick ratio of 1.08 and a debt-to-equity ratio of 0.21. The firm has a 50-day moving average price of €18.80 and a 200-day moving average price of €16.97.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Friday, May 8th. The company reported €0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). The company had revenue of €273.57 million during the quarter. Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%.Stevanato Group’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. Equities analysts anticipate that Stevanato Group S.p.A. will post 0.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on STVN shares. Weiss Ratings upgraded shares of Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 16th. TD Cowen raised shares of Stevanato Group to a “strong-buy” rating in a research note on Wednesday, June 17th. Finally, Wolfe Research assumed coverage on shares of Stevanato Group in a report on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Stevanato Group currently has an average rating of “Buy”.

Institutional Investors Weigh In On Stevanato Group

Institutional investors have recently made changes to their positions in the company. State of Wyoming grew its stake in shares of Stevanato Group by 39,216.7% in the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after buying an additional 2,353 shares in the last quarter. GW&K Investment Management LLC lifted its stake in Stevanato Group by 76.2% in the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock valued at $49,000 after acquiring an additional 1,055 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Stevanato Group in the third quarter valued at approximately $68,000. Fifth Third Bancorp increased its stake in shares of Stevanato Group by 22.6% during the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after purchasing an additional 773 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Stevanato Group by 1,268.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock valued at $112,000 after purchasing an additional 4,250 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.